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Abstract 
 
Osteoarthritis (OA), osteochondrosis (OC) and synovial sepsis in horses cause loss of 
function and pain. Reliable biomarkers are required to achieve accurate and rapid 
diagnosis, with synovial fluid (SF) holding a unique source of biochemical information. 
Nuclear magnetic resonance (NMR) spectroscopy allows global metabolite analysis of a 
small volume of SF, with minimal sample pre-processing using a non-invasive and non-
destructive method. Equine SF metabolic profiles from both non-septic joints (OA and OC) 
and septic joints were analysed using 1D 1H NMR spectroscopy. Univariate and 
multivariate statistical analyses were used to identify differential metabolite abundance 
between groups. Metabolites were annotated via 1H NMR using 1D NMR identification 
software Chenomx, with identities confirmed using 1D 1H and 2D 1H 13C NMR. Multivariate 
analysis identified separation between septic and non-septic groups. Acetate, alanine, 
citrate, creatine phosphate, creatinine, glucose, glutamate, glutamine, glycine, 
phenylalanine, pyruvate and valine were higher in the non-septic group whilst glycylproline 
was higher in sepsis. Multivariate separation was primarily driven by glucose; however 
PLS-DA plots with glucose excluded demonstrated the remaining metabolites were still 
able to discriminate the groups. This study demonstrates a panel of synovial metabolites 
can distinguish between septic and non-septic equine SF, with glucose the principal 
discriminator. 
 
Keywords: metabolomics, equine, synovial fluid, osteoarthritis, osteochondrosis, sepsis, 
nuclear magnetic resonance 
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Introduction 
Conditions affecting the articular joints are common in horses resulting in loss of function, 
chronic pain and/or subsequent inability to work, all of which represent economic and 
welfare concerns. These pathologies include osteoarthritis (OA), osteochondrosis (OC) 
and synovial sepsis, which can be life-threatening.1 Despite these conditions having a high 
prevalence and clinical relevance, diagnosis, staging, monitoring and determination of an 
accurate prognosis remain a challenge for practising veterinarians. Therefore, in order to 
differentiate equine articular joint pathologies, there is a need to identify reliable 
biomarkers of disease. Synovial fluid (SF) is located within the articular joint cavity, 
providing a pool of nutrients for surrounding tissues but primarily serving as a biological 
lubricant, containing molecules with low-friction and low-wear properties to articular 
surfaces.2 As SF is in close proximity to articular tissues primarily altered during joint 
pathology, this bio-fluid is an important source of biomarker discovery.3,4 
Reduced levels of glucose in human and equine SF, due to an increase in synovial and 
neutrophil cell glycolytic activity in severe inflammation or infection, have previously been 
identified, with a serum-synovial glucose difference of ˃2.2 mmol/L considered supportive 
of a diagnosis of synovial sepsis.5,6 However, this parameter is non-specific and can be 
influenced by multiple variables, including synovial necrosis, diet, pain and white blood cell 
count. Elevations in lactate during the acute infection phase have previously been 
identified in SF of septic human and equine joints, due to an increase in the consumption 
of glucose and subsequent production of lactate within an anaerobic environment.7,8 
However, other studies have not been able to differentiate septic and non-septic 
arthropathies based on lactate levels alone.9,10 Synovial D-lactate (produced via bacterial 
fermentation and a stereoisomer of mammalian L-lactate) was recently found to be unable 
to aid diagnosis of equine synovial sepsis.11 
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At present no specific biomarkers have been identified for equine OA and therefore none 
are used as a diagnostic aid in clinical practice. Potential OA markers of interest include 
cartilage oligomeric matrix proteinase (COMP) and matrix metalloproteinases (MMPs) 
which have both been identified as elevated in human OA SF.12 Although detection of 
active MMPs in horses has demonstrated important potential in diagnosis, conversely 
decreased levels of COMP have been identified in equine OA and found unable to stage 
the disease.13,14 In equine OC, elevated levels of a C-propeptide of cartilage type II 
procollagen and osteocalcin have shown potential as a diagnostic aid although these 
markers have not translated to clinical practice.15–17 However, these protein markers 
identify pathology following significant cartilage degradation and bone remodelling 
opposed to an early disease state where potential intervention would prove most 
beneficial.  
Metabolomics encompasses the comprehensive profiling of metabolic changes, including 
the study of metabolic pathways and quantification of unique biochemical molecules, 
within living systems.18 These small molecule metabolites include metabolic intermediates, 
secondary metabolites, hormones and other signalling molecules.19 A major advantage of 
nuclear magnetic resonance (NMR) spectroscopy over other techniques, i.e. mass 
spectrometry, is the analysis of native samples with a minimal level of sample preparation 
using a non-invasive and non-destructive method, subsequently producing results which 
are more reproducible and robust.20 Thus this methodology holds huge potential in the 
analysis of bio-fluids to characterise the global metabolic profiles of various pathologies.21 
Hugle et al. (2012) previously carried out NMR spectroscopy using human SF, identifying 
that septic arthritis SF could be distinguished from non-septic arthritis SF via principal 
component analysis (PCA), although they were unable to identify the specific metabolites 
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responsible for this discrimination.22 To date, only one peer reviewed publication has used 
NMR to investigate the whole metabolic profile of equine SF, comparing normal and 
osteoarthritic SF.23 Lacitignola et al. identified ten differentially abundant metabolites which 
included elevated levels of glucose and lactate in OA. No studies have however analysed 
equine SF using NMR to investigate synovial sepsis or OC, concurrently analysed the 
metabolic profiles of multiple equine articular pathologies or used multivariate analysis to 
investigate the metabolic profile as a whole. 
In this study we have used global metabolite identification using 1H NMR to identify 
potential metabolite biomarkers that allow differentiation between equine articular joint 
pathologies, potentially aiding accurate diagnosis. 
 
Methods 
 
Patient groups and SF collection 
 
Following ethical approval and owner consent, excess aspirated SF (collected during 
clinical diagnostic investigations) was analysed from joints of horses presenting to The 
Philip Leverhulme Equine Hospital, University of Liverpool between 2014 and 2016. SF 
was aspirated for diagnostic purposes from the affected joints at the start of surgical 
arthroscopy under general anaesthesia with 500 µl of excess SF submitted for NMR 
metabolomic analysis. Pathological joints included the femorotibial, glenohumeral, 
metacarpophalangeal, metatarsophalangeal and tarsocrural joints. Horses were divided 
into two main groups of joint pathology, septic and non-septic. The septic group was 
subdivided into six horses with synovial sepsis following a local penetrating wound and 
one foal diagnosed with synovial sepsis secondary to haematogenous spread. The non-
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septic group consisted of four horses diagnosed with OA, two with meniscal tears and 
concurrent OA (MT) and six with OC. Diagnoses were determined via a combination of 
radiography, ultrasonography, arthroscopy and SF total protein, cytology and/or bacterial 
culture as previously described.11 SF was immediately placed into uncoated 1.5 ml 
collection tubes and processed within an hour of collection. Particulate and cells were 
removed from the SF by centrifugation (4oC, 2540 g for 5 mins) then the cell-free 
supernatant transferred to a clean uncoated 1.5 ml collection tube, snap-frozen using 
liquid nitrogen and stored at -80oC. Samples were spun to ensure removal of cellular 
debris which was critical to eliminate variance due to bacterial contamination in septic 
joints. To ascertain the most reproducible and robust collection protocol, biologically 
identical SF underwent +/- centrifugation and supernatant removal followed by freezing 
using various methods at different temperatures. Multivariate statistical analysis of these 
samples indicated that the above method was most robust at reducing variance due to 
sample handling/processing (data not shown). 
 
Sample preparation 
NMR samples were prepared within 48 hours of acquisition. 300 µl of thawed SF was diluted 
to a final volume containing 50% (v/v) SF, 40% (v/v) dd 1H2O (18.2MΩ), 10% (v/v) 1M PO43- 
pH 7.4 buffer (Na2HPO4, VWR International Ltd., Radnor, Pennsylvania, USA and NaH2PO4, 
Sigma-Aldrich, Gillingham, UK) in deuterium oxide (2H2O, Sigma-Aldrich) and 0.0025% (v/v) 
sodium azide (NaN3, Sigma-Aldrich). Samples were vortexed for 1 min, centrifuged at 
13,000 g and 4˚C for 2 mins and 590 µl transferred (taking care not to disturb any pelleted 
material) into 5 mm outer diameter NMR tubes using a glass pipette. 
NMR Acquisition  
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One dimensional 1H NMR spectra with Carr-Purcell-Meiboom-Gill (CPMG) filter to 
attenuate signals from macromolecules such as albumins were acquired using a standard 
vendor pulse sequence (cpmgpr1d) on a 600 MHz NMR Bruker Avance III spectrometer 
with a TCI cryoprobe and chilled Sample-Jet autosampler. Spectra were acquired at 25˚C, 
with a 4 s interscan delay, 32 transients and a 15 ppm spectral width. Software for 
acquisition and processing was carried out using Topsin 3.1 and IconNMR 4.6.7 with 
automated phasing and baseline correction and a standard vendor processing routine 
(exponential window function with 0.3 Hz line broadening).  
Metabolite Annotation and Identification 
All spectra were scrutinised to ensure spectra met community recommended quality 
control criteria prior to inclusion in statistical analysis.24 Quality control criteria included a 
flat baseline, water signal less than 0.4 ppm wide and line-width half heights of 
representative beta anomeric glucose doublet all within one standard deviation. Spectra 
were then divided into spectral regions or ‘buckets’ according to metabolite annotation 
from Chenomx NMR Suite 8.2 (330-mammalian metabolite library) with buckets attributed 
to multiple metabolites where peaks were found to overlap. Each spectrum was divided 
into 306 buckets with the intensity of each bucket divided by the bucket width to negate the 
intensity variance. Buckets were normalised to the median and Pareto scaled prior to 
statistical treatment. Metabolites annotated in Chenomx were also confirmed by a mixture 
of 1H 1D NMR and, where possible, to in-house 2D 1H 13C Heteronuclear Single Quantum 
Coherence NMR standards. Spectra and metabolite assignments including HMDB IDs and 
annotation level is all available in the Metabolights repository 
(www.ebi.ac.uk/metabolights/MTBLS543) and shown in table 2.25 Among the metabolites 
identified was ethanol, likely through contamination during SF aspiration following surgical 
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sterilisation. Therefore, for multivariate analysis the buckets attributed to ethanol were 
omitted. 
Statistical Analysis 
SF spectra were divided into two groups: non-septic and septic. Further separation of the 
groups was not possible due to limited sample number in this study. T-tests and partial-
least squares discriminant analysis (PLS-DA) were carried out using MetaboAnalyst 3.5 
(http://www.metaboanalyst.ca) which uses the R package of statistical computing 
software.26 For t-tests, p < 0.05 was considered statistically significant following correction 
for multiple testing using the Benjamini-Hochberg false discovery rate method.27 Box plots 
were carried out using the software package SPSS 22. Quantile and PCA plots were 
produced using standard analytical routines in the software package R (r-cran.org). 
 
Results 
 
Group limitations 
 
The patient groups were restricted to two main groups; septic or non-septic (Table 1) due 
to a lack of sufficient cases of differing sub-diagnoses. The joints from which each sample 
was collected were noted, however, without a larger study size no separate grouping for 
differing joints was attempted. 
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Table 1. Table detailing further clinical characteristics of the group patients. 
 
Abbreviations: Groups, OA = Osteoarthritis, MT = Meniscal tear and concurrent OA, OC = 
Osteochrondrosis; Sex, M = Male, F = Female; Joints, GH = Glenohumeral, MCP = 
Metacarpophalangeal. FT = Femorotibial, MTP = Metatarsophalangeal and TC = 
Tarsocrural. 
 
Metabolite annotation and identification 
 
NMR spectra for all groups showed a consistent set of metabolite signals present with 
multiple metabolites identified from 1D multiplet pattern overlap (Figure 1). The metabolite 
abundances within the septic group were less variable than the non-septic group, which is 
perhaps expected given the non-septic group included samples from two separate 
diagnoses (OA and OC). Of the 306 spectral bins in each extract, 203 (66%) were annotated 
to 71 metabolites, with identification confirmed for 55 of these metabolites (Table 2).  
  Main Groups Sub-Groups 
  
Septic Non-Septic 
Septic Non-Septic 
  
Wound 
Sepsis 
Haematogenous 
Sepsis 
OA 
MT with 
OA 
OC 
Number 7 12 6 1 4 2 6 
Mean 
Age 
6 years 
10 months 
7 years 
7 months 
7 years 
11 months 
0 years 
2 months 
10 years 
6 months 
12 years 
 0 months 
4 years 
6 months 
Sex 7M 6F, 6M 6M 1M 1F, 3M 1F, 1M 4F, 2M 
Joint 
 
1 x GH 
1 x MCP 
1 x MTP 
4 x TC 
 
2 x GH 
3 x MCP 
4 x FT 
1 x MTP 
2 x TC 
1 x MCP 
1 x MTP 
4 x TC 
1 x GH 
2 x GH 
1 x FT 
1 x MTP 
2 x FT 
3 x MCP 
1 x FT 
2 x TC 
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Figure 1. Quantile plots of OA/OC (Non-Septic), sepsis and all spectra depicting the median 
spectral plot (black line) and variation from the median within each group (yellow to red 
scale) for the full spectral range (9.0 - 0.5 ppm) and more detailed regions depicting selected 
peaks from three differentially abundant metabolites, glucose, glutamine and alanine. 
Variation within the full spectra can most clearly be seen at 0.8 ppm. 
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Table 2. Metabolites annotated in synovial fluid by Chenomx, metabolites subsequently 
identified using an in-house library are indicated by the Metabolomics Standards Initiative 
(MSI) level 1.25 
Database Identifier Metabolite Identification Reliability 
HMDB00001  1-Methylhistidine  MS Level 2 
HMDB59655  2-Hydroxyglutarate  MS Level 2 
HMDB11743  2-Phenylpropionate  MS Level 2 
HMDB00357  3-Hydroxybutyrate MS Level 2 
HMDB00355  3-Hydroxymethylglutarate  MS Level 2 
HMDB01149  5-Aminolevulinate MS Level 2 
HMDB00042  Acetate MS Level 1 
HMDB00060  Acetoacetate MS Level 2 
HMDB01890  Acetylcysteine  MS Level 2 
HMDB01432  Agmatine  MS Level 2 
HMDB00729  Alpha-Hydroxyisobutyrate MS Level 2 
HMDB00186  Alpha-Lactose  MS Level 2 
HMDB00043  Betaine  MS Level 1 
HMDB00030  Biotin  MS Level 1 
HMDB00094  Citrate MS Level 1 
HMDB00064  Creatine  MS Level 1 
HMDB00562  Creatinine  MS Level 1 
HMDB00143  D-Galactose  MS Level 2 
HMDB00122  D-Glucose  MS Level 1 
HMDB00108  Ethanol  MS Level 1 
HMDB00142  Formate MS Level 2 
HMDB00663  Glucarate MS Level 2 
HMDB01401  Glucose 6-phosphate  MS Level 2 
HMDB00131  Glycerol MS Level 1 
HMDB00123  Glycine  MS Level 1 
HMDB00721  Glycylproline  MS Level 2 
HMDB00128  Guanidoacetate MS Level 2 
HMDB00870  Histamine  MS Level 2 
HMDB00764  Hydrocinnamate MS Level 2 
HMDB00678  Isovalerylglycine  MS Level 2 
HMDB00190  Lactate MS Level 1 
HMDB00161  L-Alanine  MS Level 1 
HMDB00646  L-Arabinose  MS Level 2 
HMDB00062  L-Carnitine  MS Level 2 
HMDB00174  L-Fucose  MS Level 2 
HMDB00148  L-Glutamate MS Level 1 
HMDB00641  L-Glutamine MS Level 1 
HMDB00177  L-Histidine  MS Level 1 
HMDB00687  L-Leucine  MS Level 1 
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HMDB00159  L-Phenylalanine  MS Level 1 
HMDB00167  L-Threonine  MS Level 2 
HMDB00158  L-Tyrosine  MS Level 1 
HMDB00883  L-Valine  MS Level 1 
HMDB01389  Melatonin  MS Level 2 
HMDB01238  N-Acetylserotonin  MS Level 2 
HMDB02055  o-Cresol  MS Level 2 
HMDB00210  Pantothenic acid  MS Level 2 
HMDB00821  Phenylacetylglycine  MS Level 2 
HMDB01511  Phosphocreatine  MS Level 2 
HMDB00239  Pyridoxine  MS Level 2 
HMDB00243  Pyruvate MS Level 1 
HMDB00635  Succinylacetone  MS Level 2 
HMDB00262  Thymine  MS Level 1 
HMDB01878  Thymol  MS Level 2 
HMDB00294  Urea  MS Level 1 
 
Statistical analysis and differentially abundant metabolites. 
Of the 306 identified peaks, 180 were found to be differentially abundant between septic and 
non-septic groups when analysed using a univariate t-test, p < 0.05, with 98 peaks assigned 
to 26 different metabolites (table S1). 
Unsupervised multivariate analysis (PCA) identified clear variance between spectra from 
septic and non-septic joint pathologies, forming two distinct clusters (Figure 2). 95% of the 
variance was explained by seven principal components (PCs) with PC1 and PC2 explaining 
a combined 71.89% of variance within the data. Although the analysis between groups was 
limited to a binary diagnosis (septic vs non-septic) to explore the variance in metabolite 
profile for SF aspirated from horses with differing underlying conditions, the PCA score plots 
were coloured in terms of either main diagnosis (Binary) or sub-diagnosis (five groups). 
Within the non-septic group, samples obtained from joints with OA and associated meniscal 
tears were found to cluster together. In addition, despite a separate aetiology, SF obtained 
from a foal with haematogenous sepsis clustered with SF collected from joints diagnosed 
with sepsis subsequent to penetrating wounds.  
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Supervised multivariate discriminant analysis using PLS-DA plots of the known 
metabolites indicated that the variance was heavily influenced by glucose (Figure 3a and 
b), with 23 of the 25 most influential buckets attributed to glucose peaks. The optimal 
model comprised two components with reasonable predictive power (R2 = 0.85, Q2 = 0.72). 
Omitting glucose signals from the analysis gave rise to a somewhat lower predictive model 
(R2 = 0.70, Q2 = 0.45 fit with 1 component) (Figure 3c). From the glucose free model, 
metabolites acetate, glycylproline, glycine, citrate, creatinine and alanine were among the 
most influential (Figure 3d). 
 
Both univariate and multivariate analysis were compared to identify differentially abundant 
metabolites. Metabolite peaks identified as either significantly different (p < 0.05) via t-test 
or in the top 25 variables of influence (VIP) via glucose excluded PLS-DA were then 
attributed to a genuine differentially abundant metabolite change if the individual metabolite 
peak changes correlated. In total a panel of 13 metabolites were identified as being 
differentially abundant between septic and non-septic groups. Acetate, alanine, citrate, 
creatine phosphate, creatinine, glucose, glutamate, glutamine, glycine, phenylalanine, 
pyruvate and valine were higher in the non-septic group whilst glycylproline was higher in 
synovial sepsis. 
PCA analysis of OA and OC sub-groups suggested that, bar one sample, they may cluster 
separately and may therefore demonstrate distinctive metabolomes. However, with this 
modest group size no significant differences in metabolites (p < 0.05) were identified by 
univariate analysis (data not shown). 
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Figure 2. Principal component analysis (PCA) scores plot of septic (blue) and non-septic 
(red) SF samples. Samples with meniscal tear or haematogenous sepsis sub-diagnoses 
for OA and sepsis respectively are highlighted in each group with a thick black outline, OC 
are distinguished from OA by highlight shade. 
 
 
 
15 
 
 
 
 
Figure 3. (a)  PLS-DA plots of OA/OC vs sepsis using only metabolite annotated buckets - 
first two components shown out of a total of two components used to fit the model (R2 = 
0.85, Q2 = 0.72). (b) VIP scores for the 25 most influential buckets of PLS-DA. (c) PLS-DA 
plots of OA/OCD vs sepsis using only metabolite annotated/identified buckets with all 
glucose buckets excluded - first two components shown. It should be noted that only one 
component was used to fit the model (R2 = 0.70, Q2 = 0.45). (d) VIP scores for the 25 most 
influential buckets of glucose-excluded PLS-DA.
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Figure 4. Boxplots of key metabolites; shown as relative intensities corresponding to the most representative peak for each metabolite. 
T-test: * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.
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Discussion 
 
Despite OA, OC and synovial sepsis having a high prevalence and clinical relevance, 
diagnosis, staging, monitoring and determination of an accurate prognosis remain a 
challenge for practising veterinarians. Therefore, to differentiate equine articular joint 
pathologies, there is a need to identify reliable biomarkers of disease. To aid equine 
synovial sepsis diagnosis, currently recognised markers of glucose and lactate are 
considered to be non-specific and unreliable respectively.8,10 In addition, clinically 
assessing response to treatment of septic joints can be challenging, with differentiating 
horses with continued lameness from a non-resolving sepsis to those with a resolving 
sepsis but ongoing significant inflammation, difficult. Therefore, reliable metabolic markers 
of sepsis may aid as part of a longitudinal clinical assessment. 
 
In this study it has been shown that the metabolite profile of equine SF is able to 
discriminate between septic and non-septic joint pathologies. A panel of thirteen 
metabolites was identified which were differentially abundant between these two groups. 
These metabolites may in turn prove beneficial in an equine clinical setting as a diagnostic 
aid as well as monitoring response to treatment and assessing prognosis. Ideally this 
could be carried out through field tests, similar to those produced and used for equine bio-
fluids for metabolites glucose and lactate, urinalysis and the protein inflammatory marker 
serum amyloid A.28–31 No metabolite abundances were identified to be statistically different 
between OA and OC sub-groups. However, the PCA analysis suggested that, bar one 
sample, OC and OA metabolite profiles were different and thus may demonstrate 
distinctive metabolomes sufficient to apply robust statistical models such as PLS-DA. This 
can only be tested with a larger sample size which was not possible on this modest subset 
of patients. 
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The PLS-DA VIP scores revealed spectral peaks assigned to glucose were highly 
represented as a discriminant of joint sepsis (23/25 of the most influential peaks). Reduced 
levels of glucose in human and equine SF, due to an increase in synovial and neutrophil 
cell glycolytic activity in severe inflammation or infection, have previously been identified, 
with a serum-synovial glucose difference of ˃2.2 mmol/L considered supportive of a 
diagnosis of synovial sepsis.5,6 Glucose is, however, a non-specific parameter and can be 
influenced by multiple other variables.8 However, PLS-DA analysis with all glucose 
influenced spectral peaks omitted revealed there to still be a modest separation between 
the groups, thus indicating the differentiated metabolomes are driven by a panel of 
metabolites, and potential septic markers, opposed to glucose alone. 
 
Previous studies have described mixed results as to whether elevated synovial lactate can 
be used to help distinguish synovial sepsis 7–10. In this study we did not identify lactate 
abundance to be different between the septic and non-septic groups, therefore providing 
further evidence that lactate is an unreliable marker for synovial sepsis. 1H NMR 
spectroscopy is not able to distinguish D-lactate from L-lactate and consequently we are 
unable to draw any conclusions on the specific levels of bacterially derived D-lactate within 
the groups. 
 
In this study the majority of differentially abundant metabolites were found to be reduced in 
sepsis compared to the non-septic group. However, glycylproline was elevated in synovial 
sepsis. Glycylproline is a dipeptide end product of the catabolism of collagen.32 Following 
synovial infection and an insufficient immunological response, collagen catabolism is 
upregulated through a high cytokine concentration increasing the release of matrix 
metalloproteinases and other collagen-degrading enzymes from within the host.33 Elevated 
19 
 
levels in markers of collagen destruction in synovial sepsis over non-septic joint 
pathologies have been identified previously, with one study demonstrating increased 
synovial levels of the collagen degradation marker crosslinked C-telopeptide fragments of 
type II collagen (CTX-II) in longitudinal samples of a patient with septic arthritis compared 
to osteoarthritic patients’ SF.34 Thus glycylproline, in combination with other 
metabolite/protein derived markers of collagen catabolism, may aid clinical diagnosis of 
synovial sepsis. Following on from this study, further investigation using mass 
spectrometry analysis would complement these results as the identified degradation of 
extracellular matrix may provide lipid and carbohydrate profiles of interest. 
 
All raw NMR spectral data and associated annotations which contributed to this study have 
been deposited with the open access online repository Metabolights, curated by the 
European Bioinformatics Institute (EBI), including acquisition and processing parameters 
with all metabolites identified clearly reported. The authors feel this transparent, gold 
standard approach to data submission to independent bioinformatics specialists, such as 
the EBI, should be further encouraged within the NMR metabolomics field, in line with 
other ‘omics’ journal submissions. 
 
Study limitations 
 
Modest sample size prohibited further analysis of metabolome differences between OA 
and OC or between wound sepsis and haematogenous sepsis. Similarly, SF with OA and 
associated meniscal tears were found to cluster together although we are unable to 
conclude that SF collected from femorotibial joints with meniscal tears form a distinct 
metabolome as only two samples were available for inclusion within this study. This is of 
particular interest as a diagnostic aid for meniscal tears would have a practical clinical 
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implication within veterinary medicine which could also translate to human medicine. It is 
our hope that additional studies will provide further information and enable more stringent 
analyses to be undertaken. Furthermore, due to limited sample size SF was aspirated from 
a range of joints which may lead to variation in data due to biomechanical differences 
between joints. Again, a larger sample size would enable a greater understanding as to 
what influence joint location has on the metabolome and a stricter control of site of sample 
collection (if necessary) and thus enable further information to be extracted from the 
metabolic profiles. In addition, during the joint pathologies studied there are likely to be 
changes to exercise and diet which may alter the metabolome of SF, although this 
influence is likely to be minimal compared to the significant metabolic influence of the 
localised joint pathology. 
 
During this study we were unable to compare the SF of the joint pathologies of interest to a 
normal group. In equine clinical practice only pathological joints are aspirated during 
diagnostic investigations. Thus, under current UK ethical guidelines, no normal SF from 
living horses was available for analysis. Post-mortem SF cannot be defined as having a 
normal metabolome due to the anaerobic changes that take place following death, 
including artefactual changes in the abundance of glucose and lactate, two key 
metabolites of interest during sepsis. 
 
Conclusion 
 
This paper is the first to use NMR-led metabolomics to analyse equine SF with multiple 
pathologies and demonstrates that NMR-led metabolomics is an effective technique for 
analysis of equine SF collected within a clinical veterinary environment. Furthermore, this 
study demonstrates a panel of synovial metabolites which can distinguish between septic 
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and non-septic equine SF, with glucose the principal discriminator. To translate this into a 
diagnostic aid a wider study with participants with less common diagnoses are required to 
improve the diagnostic power. 
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